Abstract:Docetaxel is the first-line chemotherapy agent for metastatic prostate cancer. However, the emergence of resistance diminishes its efficacy and limits the survival benefit. Quercetin is a dietary flavonoid which has been shown to have multiple anti-cancer effects. Also, quercetin has been reported to reverse chemo-resistance in many other cancers. This study was to determine whether quercetin could reverse docetaxel resistance in prostate cancer cells and xenograft models, thereby exploring the underlying mechanism. Depending on the docetaxel-resistant cells (LNCaP/R, PC-3/R) which were established from docetaxel-sensitive cells (LNCaP, PC-3), it was demonstrated that quercetin could reverse docetaxel resistance in prostate cancer on proliferation, colony formation, migration, invasion and apoptosis. Although single docetaxel application had little effect on docetaxel-resistant cells, combining docetaxel with quercetin was significantly effective. Combination therapy could maximally inhibited PI3K/Akt pathway and promoted apoptosis. As shown by in-vivo study, xenograft tumors treated by docetaxel with quercetin had poorest growth. Then, to investigate the underlying mechanisms, the differences among parental cells, docetaxel-resistant subclones and quercetin treated resistant subclones were evaluated. It was found that docetaxel-resistant subclones had stronger activation of androgen receptor and PI3K/Akt pathway, more remarkable mesenchymal and stem-like cell phenotypes, and more P-gp expression than that of parental cells. Interestingly, quercetin could reverse these transformations. Our data revealed that quercetin had docetaxel-resistance reversal effect both in vitro and in vivo and provided in-depth support for clinical use of quercetin in docetaxel-resistant prostate cancer.

Reversal of Docetaxel Resistance in Prostate Cancer by Notch Signaling Inhibition

Inhibition of Notch Pathway Enhances the Anti-Tumor Effect of Docetaxel in Prostate Cancer Stem-Like Cells

Sirna-Mediated Silencing of Notch-1 Enhances Docetaxel Induced Mitotic Arrest and Apoptosis in Prostate Cancer Cells.

Silencing Notch-1 Induces Apoptosis and Increases the Chemosensitivity of Prostate Cancer Cells to Docetaxel Through Bcl-2 and Bax

Quercetin reverses docetaxel resistance in prostate cancer via androgen receptor and PI3K/Akt signaling pathways

Establishment and Characterization of a Docetaxel-Resistant Human Prostate Cancer Cell Line.

Pharmacological Inhibition of the Notch Pathway Enhances the Efficacy of Androgen Deprivation Therapy for Prostate Cancer.

Docetaxel Resistance in Prostate Cancer: Taking It Up a Notch.

NOTCH1 signaling promotes chemoresistance via regulating ABCC1 expression in prostate cancer stem cells

CNTN-1 promotes docetaxel resistance and epithelial-to-mesenchymal transition via the PI3K/Akt signaling pathway in prostate cancer

Docetaxel resistance-derived LINC01085 contributes to the immunotherapy of hormone-independent prostate cancer by activating the STING/MAVS signaling pathway

Identification of Biomarkers, Pathways and Potential Therapeutic Target for Docetaxel Resistant Prostate Cancer

PAF1-mediated transcriptional reprogramming confers docetaxel resistance in advanced prostate cancer

Nanoways to overcome docetaxel resistance in prostate cancer

INPP4B Reverses Docetaxel Resistance and Epithelial-to-mesenchymal Transition Via the PI3K/Akt Signaling Pathway in Prostate Cancer.

RBPJ Contributes to Acquired Docetaxel Resistance in Prostate Cancer Cells

Exploration and Identification of Potential Therapeutic Targets and Biomarkers for Docetaxel Resistant Prostate Cancer

Long Non-Coding RNA PCDRlnc1 Confers Docetaxel Resistance in Prostate Cancer by Promoting Autophagy

Evaluation of Docetaxel-Sensitive and Docetaxel-Resistant Proteomes in PC-3 Cells

Saikosaponin-d mediates FOXG1 to reverse docetaxel resistance in prostate cancer through oxidative phosphorylation

The Role of Testicular Nuclear Receptor 4 in Chemo-Resistance of Docetaxel in Castration-Resistant Prostate Cancer.